News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2015

Ad-hoc: Epigenomics Reaches 99.5 % Adherence for Epi proColon® in ADMIT Study

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 58 KB   Berlin – Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces results from the ADMIT trial (ADherence to Minimally Invasive Testing – NCT02251782) for its non-invasive blood-based test for colorectal cancer (CRC) screening, Epi proColon®. The study demonstrated […]

Read more

Epigenomics Reaches 99.5 % Adherence for Epi proColon® in ADMIT Study

PDF 145 KB   Berlin – Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces results from the ADMIT trial (ADherence to Minimally Invasive Testing – NCT02251782) for its non-invasive blood-based test for colorectal cancer (CRC) screening, Epi proColon®. The study demonstrated a 99.5% rate of adherence to CRC screening using Epi proColon®, while the […]

Read more

Epigenomics receives EUR 2.8m grant for Validation of Lung Cancer Biomarkers in Blood Plasma

PDF 302 KB   Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company will receive an EU grant under the industrial leadership Horizon 2020 research and innovation program for SME (Small and Medium-Sized Enterprises). The grant duration is […]

Read more

Epigenomics AG Reports Results for the Financial Year Ended December 31, 2014 and Provides Outlook for 2015

PDF 112 KB Epi proColon® approved for commercialization in China US Approval: ADMIT trial fully enrolled; expected to report data in Q2 2015 Strong commitment from partners; EUR 4.2 million equity investment by BioChain Solid year-end financial position; liquidity at year end 2014 EUR 7.5 million

Read more

Epigenomics Announces Completion of Enrollment in Epi proColon® ADMIT Trial

PDF 112 KB Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced the completion of subject enrollment into its ADMIT trial (ADherence to Minimally Invasive Testing – NCT02251782) for its non-invasive blood-based test for colorectal cancer (CRC) screening, Epi proColon®. The […]

Read more